Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging

Area of Science:

• Oncology
• Genomics
• Biostatistics

Background:

• Current non-small cell lung cancer (NSCLC) staging relies on clinicopathologic factors, with limited validated improvement in early-stage risk stratification.
• Molecular biomarkers are increasingly adopted in NSCLC management, but their integration into staging systems requires further evaluation.

Purpose of the Study:

• To evaluate the integration of a clinically validated molecular prognostic classifier into conventional staging for non-small cell lung cancer (NSCLC).
• To develop and validate a novel TNMB staging system (incorporating a 14-gene molecular prognostic classifier) and compare its performance against the seventh and eighth editions of the TNM staging system.

Main Methods:

• A novel TNMB staging system was developed using data from 321 NSCLC patients.
• The TNMB system, integrating a 14-gene molecular prognostic classifier, was validated in an independent multicenter cohort of 1373 patients.
• Performance was compared with the seventh and eighth TNM editions using reclassification metrics.

Main Results:

• The TNMB staging system significantly enhanced identification of high-risk patients compared to the eighth TNM edition, showing a net reclassification improvement of 0.33.
• TNMB demonstrated superior survival prediction, with a relative integrated discrimination improvement of 22.1% and improved calibration.
• The seventh and eighth TNM editions showed minimal improvement in net reclassification and relative integrated discrimination, with the eighth edition worsening calibration.

Conclusions:

• Integrating a molecular prognostic classifier into staging significantly improves the identification of high-risk NSCLC patients and survival predictions.
• The TNMB staging system offers enhanced risk stratification for early-stage NSCLC, potentially leading to more effective adjuvant therapy application and improved survival.